Literature DB >> 26431836

Molecular Pathogenesis of Peripheral T Cell Lymphoma.

Mamiko Sakata-Yanagimoto1, Shigeru Chiba2.   

Abstract

Understanding the molecular pathogenesis of peripheral T cell lymphomas (PTCLs) has lagged behind that of B cell lymphomas due to disease rarity. However, novel approaches are gradually clarifying these mechanisms, and gene profiling has identified specific signaling pathways governing PTCL cell survival and growth. For example, genetic alterations have been discovered, including signal transducer and activator of transcription (STAT)3 and STAT5b mutations in several PTCLs, disease-specific ras homolog family member A (RHOA) mutations in angioimmunoblastic T cell lymphoma (AITL), and recurrent translocations at the dual specificity phosphatase 22 (DUSP22) locus in anaplastic lymphoma receptor tyrosine kinase (ALK)-negative anaplastic large cell lymphomas (ALCLs). Intriguingly, some PTCL-relevant mutations are seen in apparently normal blood cells as well as tumor cells, while others are confined to tumor cells. These data have dramatically changed our understanding of PTCL origins: once considered to originate from mature T lymphocytes, some PTCLs are now believed to emerge from immature hematopoietic progenitor cells.

Entities:  

Keywords:  B cell lymphomas; Peripheral T cell lymphomas (PTCLs); T cell lymphoma

Mesh:

Year:  2015        PMID: 26431836     DOI: 10.1007/s11899-015-0289-7

Source DB:  PubMed          Journal:  Curr Hematol Malig Rep        ISSN: 1558-8211            Impact factor:   4.213


  94 in total

1.  Somatic STAT3 mutations in large granular lymphocytic leukemia.

Authors:  Hanna L M Koskela; Samuli Eldfors; Pekka Ellonen; Arjan J van Adrichem; Heikki Kuusanmäki; Emma I Andersson; Sonja Lagström; Michael J Clemente; Thomas Olson; Sari E Jalkanen; Muntasir Mamun Majumder; Henrikki Almusa; Henrik Edgren; Maija Lepistö; Pirkko Mattila; Kathryn Guinta; Pirjo Koistinen; Taru Kuittinen; Kati Penttinen; Alun Parsons; Jonathan Knowles; Janna Saarela; Krister Wennerberg; Olli Kallioniemi; Kimmo Porkka; Thomas P Loughran; Caroline A Heckman; Jaroslaw P Maciejewski; Satu Mustjoki
Journal:  N Engl J Med       Date:  2012-05-17       Impact factor: 91.245

2.  Dysregulated microRNAs affect pathways and targets of biologic relevance in nasal-type natural killer/T-cell lymphoma.

Authors:  Siok-Bian Ng; Junli Yan; Gaofeng Huang; Viknesvaran Selvarajan; Jim Liang-Seah Tay; Baohong Lin; Chonglei Bi; Joy Tan; Yok-Lam Kwong; Norio Shimizu; Katsuyuki Aozasa; Wee-Joo Chng
Journal:  Blood       Date:  2011-09-14       Impact factor: 22.113

3.  miR-135b mediates NPM-ALK-driven oncogenicity and renders IL-17-producing immunophenotype to anaplastic large cell lymphoma.

Authors:  Hironori Matsuyama; Hiroshi I Suzuki; Hikaru Nishimori; Masaaki Noguchi; Takashi Yao; Norio Komatsu; Hiroyuki Mano; Koichi Sugimoto; Kohei Miyazono
Journal:  Blood       Date:  2011-10-31       Impact factor: 22.113

4.  Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway.

Authors:  M Marzec; M Kasprzycka; X Liu; M El-Salem; K Halasa; P N Raghunath; R Bucki; P Wlodarski; M A Wasik
Journal:  Oncogene       Date:  2007-03-12       Impact factor: 9.867

5.  MiR-29a down-regulation in ALK-positive anaplastic large cell lymphomas contributes to apoptosis blockade through MCL-1 overexpression.

Authors:  Cécile Desjobert; Marie-Hélène Renalier; Julie Bergalet; Emilie Dejean; Nicole Joseph; Anna Kruczynski; Jean Soulier; Estelle Espinos; Fabienne Meggetto; Jérome Cavaillé; Georges Delsol; Laurence Lamant
Journal:  Blood       Date:  2011-04-06       Impact factor: 22.113

Review 6.  cFLIP regulation of lymphocyte activation and development.

Authors:  Ralph C Budd; Wen-Chen Yeh; Jürg Tschopp
Journal:  Nat Rev Immunol       Date:  2006-03       Impact factor: 53.106

7.  Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia.

Authors:  Mark J Kiel; Thirunavukkarasu Velusamy; Delphine Rolland; Anagh A Sahasrabuddhe; Fuzon Chung; Nathanael G Bailey; Alexandra Schrader; Bo Li; Jun Z Li; Ayse B Ozel; Bryan L Betz; Roberto N Miranda; L Jeffrey Medeiros; Lili Zhao; Marco Herling; Megan S Lim; Kojo S J Elenitoba-Johnson
Journal:  Blood       Date:  2014-05-13       Impact factor: 22.113

Review 8.  Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia.

Authors:  Omar Abdel-Wahab; Ross L Levine
Journal:  Blood       Date:  2013-05-02       Impact factor: 22.113

9.  Vav-promoter regulated oncogenic fusion protein NPM-ALK in transgenic mice causes B-cell lymphomas with hyperactive Jun kinase.

Authors:  Suzanne D Turner; Reuben Tooze; Kenneth Maclennan; Denis R Alexander
Journal:  Oncogene       Date:  2003-10-30       Impact factor: 9.867

10.  Somatic RHOA mutation in angioimmunoblastic T cell lymphoma.

Authors:  Mamiko Sakata-Yanagimoto; Terukazu Enami; Kenichi Yoshida; Yuichi Shiraishi; Ryohei Ishii; Yasuyuki Miyake; Hideharu Muto; Naoko Tsuyama; Aiko Sato-Otsubo; Yusuke Okuno; Seiji Sakata; Yuhei Kamada; Rie Nakamoto-Matsubara; Nguyen Bich Tran; Koji Izutsu; Yusuke Sato; Yasunori Ohta; Junichi Furuta; Seiichi Shimizu; Takuya Komeno; Yuji Sato; Takayoshi Ito; Masayuki Noguchi; Emiko Noguchi; Masashi Sanada; Kenichi Chiba; Hiroko Tanaka; Kazumi Suzukawa; Toru Nanmoku; Yuichi Hasegawa; Osamu Nureki; Satoru Miyano; Naoya Nakamura; Kengo Takeuchi; Seishi Ogawa; Shigeru Chiba
Journal:  Nat Genet       Date:  2014-01-12       Impact factor: 41.307

View more
  4 in total

1.  Recurrent MSC E116K mutations in ALK-negative anaplastic large cell lymphoma.

Authors:  Rebecca A Luchtel; Michael T Zimmermann; Guangzhen Hu; Surendra Dasari; Manli Jiang; Naoki Oishi; Hailey K Jacobs; Yu Zeng; Tanya Hundal; Karen L Rech; Rhett P Ketterling; Jeong-Heon Lee; Bruce W Eckloff; Huihuang Yan; Krutika S Gaonkar; Shulan Tian; Zhenqing Ye; Marshall E Kadin; Jagmohan Sidhu; Liuyan Jiang; Jesse Voss; Brian K Link; Sergei I Syrbu; Fabio Facchetti; N Nora Bennani; Susan L Slager; Tamas Ordog; Jean-Pierre Kocher; James R Cerhan; Stephen M Ansell; Andrew L Feldman
Journal:  Blood       Date:  2019-05-17       Impact factor: 22.113

2.  International Assessment of Event-Free Survival at 24 Months and Subsequent Survival in Peripheral T-Cell Lymphoma.

Authors:  Matthew J Maurer; Fredrik Ellin; Line Srour; Mats Jerkeman; N Nora Bennani; Joseph M Connors; Graham W Slack; Karin E Smedby; Stephen M Ansell; Brian K Link; James R Cerhan; Thomas Relander; Kerry J Savage; Andrew L Feldman
Journal:  J Clin Oncol       Date:  2017-10-26       Impact factor: 44.544

3.  THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors.

Authors:  Florencia Cayrol; Pannee Praditsuktavorn; Tharu M Fernando; Nicholas Kwiatkowski; Rosella Marullo; M Nieves Calvo-Vidal; Jude Phillip; Benet Pera; Shao Ning Yang; Kaipol Takpradit; Lidia Roman; Marcello Gaudiano; Ramona Crescenzo; Jia Ruan; Giorgio Inghirami; Tinghu Zhang; Graciela Cremaschi; Nathanael S Gray; Leandro Cerchietti
Journal:  Nat Commun       Date:  2017-01-30       Impact factor: 14.919

Review 4.  T-cell lymphomas, a challenging disease: types, treatments, and future.

Authors:  Helen Ma; Maher Abdul-Hay
Journal:  Int J Clin Oncol       Date:  2016-10-14       Impact factor: 3.402

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.